Study CGRP blocker effects on migraine and body nerve function
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests a CGRP-blocking antibody to see how it affects migraine symptoms and the body’s automatic (involuntary) nerve functions. It may help people with migraine who have already tried several preventive medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have migraine that is either chronic, or episodic with or without aura
- You’ve already tried at least 3 preventive (pre-migraine) medicines without enough success
- Your health insurance covers the study medicine costs
- If you are a healthy control (not a migraine patient): you must have no diagnosed chronic illness and no recent infection needing medicine
- You should not be pregnant, and you should not be breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is building a database to learn more about migraine drugs. It may help researchers find better treatments for people with episodic or chronic migraine.
This study tracks how well new migraine medications (like Aimovig, Emgality, Ajovy, Vyepti, Qulipta, and Nurtec) work in everyday use. It may help you and your doctor understand if these treatments are a good option for your migraines.
This study tests an add-on migraine medicine (eptinezumab) given in the emergency room to quickly relieve a migraine attack, in addition to the usual care. It aims to see if this approach reduces pain and prevents the migraine from coming back.
This study looks at how preventive treatments for severe migraines, like botulinum toxin injections or anti-CGRP antibody infusions, may affect thinking and quality of life. If you have frequent migraines that don't respond to other treatments, you might be able to join.
This study tests a daily pill called atogepant to see how it affects the brain and body in people with episodic migraine. It may help if you have 8 to 14 migraine days a month and haven't tried CGRP treatments before.
This trial tests a substance that activates adrenomedullin receptors, which may be a new way to treat migraines. It may help people who have migraines without aura and aren't on preventive migraine medications.
Hear when a new Episodic Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.